Page 240 - Drug Class Review
P. 240
Page 150 of 205
Drug Effectiveness Review Project
donepezil 93.4% 19.8% 17.6% 12.1% 14.3% 12.1% 8.8% donepezil 22% 13.2%
galantamine 90.7% 18.6% 19.6% 18.6% 17.5% 16.5% 16.5% Post randomization exclusions: No No; different treatment regimens precluded allocation concealment Overall loss to follow-up: 21% Loss to follow-up differential high: No galantamine 19.6% 13.4%
None ITT: Yes Yes Method NR N/A
Final Report Update 1 Authors: Wilcock et al. Year: 2003 ADVERSE EVENTS: Overall adverse effects reported: Severe adverse events • Nausea • Agitation • Vomiting • Headache • Falls • Significant differences in adverse events: ANALYSIS: ADEQUATE RANDOMIZATION: ADEQUATE ALLOCATION CONCEALMENT: BLINDING OF OUTCOME ASSESSORS: ATTRITION (overall): ATTRITION (treatment specific): Loss to follow-up: Withdrawals due to adverse events: QUALITY RATING: *primary outcome measures Alzheimer's Drugs
